Vivoryon Therapeutics AG

  • WKN: 792183
  • ISIN: DE0007921835
  • Land: Deutschland

Nachricht vom 03.09.2020 | 15:09

Vivoryon Therapeutics AG: Vivoryon Therapeutics Announces Notice of its Ordinary General Meeting of Shareholders to be Held on September 30, 2020

DGAP-News: Vivoryon Therapeutics AG / Key word(s): AGM/EGM
03.09.2020 / 15:09
The issuer is solely responsible for the content of this announcement.

Vivoryon Therapeutics Announces Notice of its Ordinary General Meeting of Shareholders to be Held on September 30, 2020
 

HALLE (SAALE) / MUNICH, GERMANY, 3 September 2020 - Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) invites all shareholders to Vivoryon Therapeutics' ordinary general meeting of shareholders to be held on Wednesday, September 30, 2020 at 11:00 am CEST, at the registered office, Weinbergweg 22, 06120 Halle (Saale), Germany.

The Meeting will include a proposed resolution to transform Vivoryon Therapeutics into a naamloze vennootschap (N.V) under Dutch law by changing official seat from Halle (Saale) to Amsterdam, the Netherlands.
 

All relevant documents are available on the company's website:

www.vivoryon.com/investors-news/ordinary-general-meeting-of-shareholders-2020


Important notice:
With regard to the ongoing COVID-19 pandemic, the company will take various precautionary measures to reduce the risk of infections. The company will provide free of charge hand disinfectant as well as masks to cover the nose and mouth for shareholders and will, subject to the spatial conditions and the number of participating shareholders, arrange the seats with adequate spacing. Additionally, food or beverages will not be offered. The company will strictly monitor the current situation and developments and may adjust measures accordingly.
 

###


For more information, please contact:
Vivoryon Therapeutics AG
Dr. Ulrich Dauer, CEO
Email: contact@vivoryon.com

Trophic Communications
Gretchen Schweitzer / Joanne Tudorica
Tel: +49 172 861 8540 / +49 171 351 2733
Email: vivoryon@trophic.eu


About Vivoryon Therapeutics AG
With 20+ years of unmatched understanding in identifying post-translational modifying enzymes that play critical roles in disease initiation and progression, Vivoryon's scientific expertise has facilitated the creation of a discovery and development engine for small molecule therapeutics. This platform has demonstrated success by developing a novel therapeutic in type 2 diabetes. In its current programs Vivoryon Therapeutics is advancing its lead product, varoglutamstat (PQ912), in Alzheimer's disease and its entire portfolio of QPCT and QPCTL inhibitors in oncology and other indications. In addition, the company pursues a development program for Meprin protease inhibitors with potential therapeutic use in fibrotic diseases, cancer and acute kidney injury.
www.vivoryon.com

Forward Looking Statements
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Vivoryon Therapeutics AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.



03.09.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Event im Fokus

14.-15.10.2020 Fachkonferenzen Finanzdienstleistungen und Technologie

11.-12.11.2020 Fachkonferenzen Software/IT und Branchenmix

Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen könnten die Fachkonferenzen im Herbst/Winter ggf. auch virtuell stattfinden.

GBC-Fokusbox

Solutiance: Hohe Wachstumsdynamik durch den Ausbau des Plattformgeschäfts erwartet

Im ersten Halbjahr 2020 konnte Solutiance den eingeschlagenen Wachstumskurs fortsetzen und im Rahmen dessen die Gesamtleistung (Umsatz zzgl. Bestandsveränderungen) um rund 75 % auf 0,66 Mio. € (1. HJ 2019: 0,38 Mio. €) erhöhen. Das Unternehmen erwartet für das Gesamtjahr durch den weiteren Ausbau der softwarebasierten Dienstleistungen einen Umsatzsprung im Vergleich zum Vorjahr auf rund 3 Mio. €. Bei einem von uns ermittelten Kursziel von 4,85 € vergeben wir das Rating KAUFEN.

News im Fokus

Continental AG veröffentlicht vorläufige Kennzahlen für das 3. Quartal 2020 und berücksichtigt nicht zahlungswirksame Wertminderungen sowie Restrukturierungsaufwendungen

21. Oktober 2020, 17:57

Aktueller Webcast

HelloFresh SE

Q3 2020 Results Webcast

03. November 2020

Aktuelle Research-Studie

Nynomic AG

Original-Research: Nynomic AG (von Montega AG): Kaufen

22. Oktober 2020